Compare JBS N.V. Class A Common Shares (JBS) vs Kenvue Inc. Common Stock (KVUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs Kenvue Inc. Common Stock — how do they compare? JBS N.V. Class A Common Shares trades at $13 (market cap $13.86B), while Kenvue Inc. Common Stock trades at $18.08 (market cap $34.11B). The key difference: Kenvue Inc. Common Stock is far larger — about 2.5× JBS N.V. Class A Common Shares's market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.38%). Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Kenvue Inc. Common Stock for 1 Days on average.
| JBS | KVUE | |
|---|---|---|
Market Cap | $13.86B | $34.11B |
Volume | 4,980,049 | 27,388,811 |
Sector | Consumer Staples | Consumer Staples |
52-Week High | $18.42 | $19.83 |
52-Week Low | $10.86 | $14.11 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $34.83B | $41.62B |
Dividend Yield | 10.38% | 4.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.
The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About Kenvue Inc. Common Stock
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →
